EP66: Statin Therapy In Australia: What's New?

Welcome to my podcast. I am Doctor Warrick Bishop, and I want to help you to live as well as possible for as long as possible. I’m a practising cardiologist, best-selling author, keynote speaker, and the creator of The Healthy Heart Network. I have over 20 years as a specialist cardiologist and a private practice of over 10,000 patients. Podcast Summary Dr. Warrick Bishop, a practicing cardiologist and author, hosts this episode to educate patients about heart health and recent changes in Australian healthcare policy. In this episode, he discusses a significant update to Australia's Pharmaceutical Benefits Scheme (PBS) regarding the availability and prescription of statins for cholesterol management. The primary focus is how the removal of eligibility restrictions on generic statins as of October 1, 2018, represents a major step forward in preventative cardiology. Key Takeaways: The PBS (Pharmaceutical Benefits Scheme) regulates pharmaceutical funding in Australia and is closely monitored due to its enormous cost to taxpayers and the government. Previous statin eligibility criteria, established in October 2006, required patients to have symptomatic conditions (heart disease, stroke, or blocked arteries) before accessing cholesterol-lowering drugs. The 2006 criteria also included specific high-risk groups such as diabetics, Aboriginal and Torres Strait Islanders, and those with strong family histories of early coronary artery disease. Patents on statins have expired since 2006, allowing generic versions to be manufactured at significantly lower costs by multiple pharmaceutical companies. As of October 1, 2018, the PBS removed all eligibility restrictions for statins, while other cholesterol-lowering drugs still maintain restrictions due to higher costs and lack of generic alternatives. The removal of restrictions enables doctors to prescribe statins based on clinical judgment and individual risk assessment, rather than waiting for patients to develop symptoms. This policy change is significant for preventative cardiology, as early intervention based on imaging results showing arterial plaque buildup can now occur without patients having to self-fund treatment. Dr. Bishop emphasizes the importance of sharing this information with the public and medical professionals, as many people may still be unnecessarily paying out-of-pocket for statins.